5 insiders buy $27 mil of Micro-Cap

Dear Fellow Investor, Studies find that multiple purchases by C-level executives signal 25.19% annualized returns – Global Business Travel Group, Inc. – SYM: GBTG Recent Price: $6.79 Insider Action: 5 insiders buy $27.4 mil in shares Description: Global Business Travel Group Inc. operates as a business-to-business (B2B) travel platform. The company engages in providing software and services to manage travel, expenses, and meetings and events for companies of all sizes. ===“Buy Alert” Issued for Tiny Micro-Cap=== This tiny micro-cap could jump to $66 a share on a takeover deal. But it's trading at just $16 a share. Two companies have already submitted letters of intent to buy them. [Get the ticker here]( === Tupperware Brands Corp. – SYM:TUP Recent Price: $6.59 Insider Action: 7 insiders buy $2 mil in shares Description: Tupperware Brands Corporation operates as a consumer products company worldwide. The company manufactures, markets, and sells design-centric preparation, storage, and serving solutions for the kitchen and home, as well as a line of cookware, knives, microwave products, microfiber textiles, water-filtration related items, and an array of products for on-the-go consumers under the Tupperware brand name. It distributes its products to approximately 70 countries primarily through independent sales force members, including independent distributors, directors, managers, and dealers. The company was formerly known as Tupperware Corporation and changed its name to Tupperware Brands Corporation in December 2005. Tupperware Brands Corporation was founded in 1946 and is headquartered in Orlando, Florida. === Bet A Million and a Half Dollars… This trading signal may be the biggest opportunity I’ve ever seen. And I’m willing to bet $1.5 million that if you can spot [“this signal”...]( You can grow your nest egg more than you ever dreamed possible. Just look for the O Sounds strange? [Click here to learn more]( === Salarius Pharmaceuticals, Inc. – SYM: SLRX Recent Price: $0.20 Insider Action: 6 insiders buy 191k shares Description: Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas. === Every Trade We Closed This Year Has Been a Winner… An Ex-Wall Street CEO has revealed his [“secret formula]([”]( for profiting during market crashes. It’s the same "formula" he’s used to get readers who followed his advice $6,130 a month on average in extra income over the past two years. [This “formula”]( is MEANT for down markets - that’s why every trade we’ve closed this year has been a winner. [Click Here to Learn More]( === "The Buck Stops Here," Behind the Markets is brought to you by Behind the Markets, LLC. If you have any questions, please contact us at support@behindthemarkets.com, or call at 800-851-1965. Behind the Markets is a newsletter offered to the public on a subscription basis. While subscribers receive the benefit of Behind the Markets opinions, none of the information contained therein constitutes a recommendation from Behind the Markets that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You further understand that we will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in Behind the Markets may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Behind the Markets’ past results are not necessarily indicative of future performance. Employees of Behind the Markets are subject to certain restrictions in transacting for their own benefit. SPECIFICALLY, EMPLOYEES ARE NOT PERMITTED TO BUY OR SELL ANY SECURITY RECOMMENDED FOR THREE (3) TRADING DAYS FOLLOWING THE ISSUE OF A REPORT OR UPDATE. Behind the Markets’ Newsletter contains Behind the Markets’ own opinions, and none of the information contained therein constitutes a recommendation by Behind the Markets that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You further understand that Behind the Markets will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in Behind the Markets Newsletter may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Behind the Markets’ past results are not necessarily indicative of future performance. DO NOT EMAIL Behind the Markets SEEKING PERSONALIZED INVESTMENT ADVICE, WHICH WE CANNOT PROVIDE. The Editor's personal investing goals and risk tolerance may be substantially different from those discussed in the Newsletter and/or circumstances may have changed by the expiration of the three day restricted period, the investment actions taken by the Editor in the accounts the Editor directly or indirectly owns may vary from (and may even be contrary to) the advice and recommendations in the Newsletter. Investing involves substantial risk. Neither the Editor, the publisher, nor any of their respective affiliates make any guarantee or other promise as to any results that may be obtained from using the Newsletter. While past performance may be analyzed in the Newsletter, past performance should not be considered indicative of future performance. No subscriber should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing the prospectus and other public filings of the issuer. To the maximum extent permitted by law, the Editor, the publisher and their respective affiliates disclaim any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations in the Newsletter prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses. The Newsletter's commentary, analysis, opinions, advice and recommendations represent the personal and subjective views of the Editor and are subject to change at any time without notice. The information provided in the Newsletter is obtained from sources which the Editor believes to be reliable. However, the Editor has not independently verified or otherwise investigated all such information. Neither the Editor, the publisher, nor any of their respective affiliates guarantees the accuracy or completeness of any such information. The Newsletter is not a solicitation or offer to buy or sell any securities. Further, the Newsletter is in no way intended to be a solicitation for any services offered by Behind the Markets Neither the Editor, the publisher, nor any of their respective affiliates are responsible for any errors or omissions in the Newsletter. Our mailing address is: Behind the Markets, LLC 4181 NW 1st Avenue, Suite 8 Boca Raton, FL 33431 Copyright © 2022 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. [Unsubscribe](